ENTERA BIO IS-0000769 (5DT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.83 Million ≈ $-2.14 Million USD) by net assets (€13.10 Million ≈ $15.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ENTERA BIO IS-0000769 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of ENTERA BIO IS-0000769 for a breakdown of total debt and financial obligations.
ENTERA BIO IS-0000769 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senstar Technologies Ltd
NASDAQ:SNT
|
0.009x |
|
QPM Energy Ltd
AU:QPM
|
-0.108x |
|
Doxa AB
ST:DOXA
|
0.055x |
|
HNA Technology Co Ltd B
SHG:900938
|
-0.009x |
|
Me2on Co. Ltd
KQ:201490
|
0.027x |
|
Stonebridge Acquisition Corp
NASDAQ:APAC
|
-0.009x |
|
MFS Investment Grade Municipal Trust
NYSE:CXH
|
0.023x |
|
IZEA Inc
NASDAQ:IZEA
|
0.024x |
Annual Cash Flow Conversion Efficiency for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ENTERA BIO IS-0000769 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 5DT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €13.10 Million ≈ $15.32 Million |
€-7.37 Million ≈ $-8.62 Million |
-0.563x | +33.33% |
| 2024-12-31 | €8.08 Million ≈ $9.45 Million |
€-6.82 Million ≈ $-7.97 Million |
-0.844x | -19.89% |
| 2023-12-31 | €10.39 Million ≈ $12.14 Million |
€-7.31 Million ≈ $-8.55 Million |
-0.704x | +33.81% |
| 2022-12-31 | €11.75 Million ≈ $13.74 Million |
€-12.50 Million ≈ $-14.61 Million |
-1.063x | -164.76% |
| 2021-12-31 | €22.57 Million ≈ $26.38 Million |
€-9.06 Million ≈ $-10.60 Million |
-0.402x | -- |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more